Literature DB >> 15292202

Heparanase uptake is mediated by cell membrane heparan sulfate proteoglycans.

Svetlana Gingis-Velitski1, Anna Zetser, Victoria Kaplan, Olga Ben-Zaken, Esti Cohen, Flonia Levy-Adam, Yulia Bashenko, Moshe Y Flugelman, Israel Vlodavsky, Neta Ilan.   

Abstract

Heparanase is a mammalian endoglycosidase that degrades heparan sulfate (HS) at specific intrachain sites, an activity that is strongly implicated in cell dissemination associated with metastasis and inflammation. In addition to its structural role in extracellular matrix assembly and integrity, HS sequesters a multitude of polypeptides that reside in the extracellular matrix as a reservoir. A variety of growth factors, cytokines, chemokines, and enzymes can be released by heparanase activity and profoundly affect cell and tissue function. Thus, heparanase bioavailability, accessibility, and activity should be kept tightly regulated. We provide evidence that HS is not only a substrate for, but also a regulator of, heparanase. Addition of heparin or xylosides to cell cultures resulted in a pronounced accumulation of, heparanase in the culture medium, whereas sodium chlorate had no such effect. Moreover, cellular uptake of heparanase was markedly reduced in HS-deficient CHO-745 mutant cells, heparan sulfate proteoglycan-deficient HT-29 colon cancer cells, and heparinase-treated cells. We also studied the heparanase biosynthetic route and found that the half-life of the active enzyme is approximately 30 h. This and previous localization studies suggest that heparanase resides in the endosomal/lysosomal compartment for a relatively long period of time and is likely to play a role in the normal turnover of HS. Co-localization studies and cell fractionation following heparanase addition have identified syndecan family members as candidate molecules responsible for heparanase uptake, providing an efficient mechanism that limits extracellular accumulation and function of heparanase.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15292202     DOI: 10.1074/jbc.M402131200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  56 in total

1.  Heparanase-neutralizing antibodies attenuate lymphoma tumor growth and metastasis.

Authors:  Marina Weissmann; Gil Arvatz; Netanel Horowitz; Sari Feld; Inna Naroditsky; Yi Zhang; Mary Ng; Edward Hammond; Eviatar Nevo; Israel Vlodavsky; Neta Ilan
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-04       Impact factor: 11.205

2.  Heparanase regulates secretion, composition, and function of tumor cell-derived exosomes.

Authors:  Camilla A Thompson; Anurag Purushothaman; Vishnu C Ramani; Israel Vlodavsky; Ralph D Sanderson
Journal:  J Biol Chem       Date:  2013-02-21       Impact factor: 5.157

3.  Heparanase augments epidermal growth factor receptor phosphorylation: correlation with head and neck tumor progression.

Authors:  Victoria Cohen-Kaplan; Ilana Doweck; Inna Naroditsky; Israel Vlodavsky; Neta Ilan
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

Review 4.  Heparanase regulation of cancer, autophagy and inflammation: new mechanisms and targets for therapy.

Authors:  Ralph D Sanderson; Michael Elkin; Alan C Rapraeger; Neta Ilan; Israel Vlodavsky
Journal:  FEBS J       Date:  2016-11-16       Impact factor: 5.542

5.  A novel human heparanase splice variant, T5, endowed with protumorigenic characteristics.

Authors:  Uri Barash; Victoria Cohen-Kaplan; Gil Arvatz; Svetlana Gingis-Velitski; Flonia Levy-Adam; Ofer Nativ; Ronen Shemesh; Michal Ayalon-Sofer; Neta Ilan; Israel Vlodavsky
Journal:  FASEB J       Date:  2009-12-09       Impact factor: 5.191

6.  Low and high affinity receptors mediate cellular uptake of heparanase.

Authors:  Olga Ben-Zaken; Itay Shafat; Svetlana Gingis-Velitski; Haim Bangio; Idil Kasuto Kelson; Tal Alergand; Yehudit Amor; Ruth Ben-Yakar Maya; Israel Vlodavsky; Neta Ilan
Journal:  Int J Biochem Cell Biol       Date:  2007-09-29       Impact factor: 5.085

7.  Cathepsin L is responsible for processing and activation of proheparanase through multiple cleavages of a linker segment.

Authors:  Ghada Abboud-Jarrous; Ruth Atzmon; Tamar Peretz; Carmela Palermo; Bedrick B Gadea; Johanna A Joyce; Israel Vlodavsky
Journal:  J Biol Chem       Date:  2008-04-30       Impact factor: 5.157

8.  Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma.

Authors:  Anurag Purushothaman; Ligong Chen; Yang Yang; Ralph D Sanderson
Journal:  J Biol Chem       Date:  2008-09-23       Impact factor: 5.157

9.  Clinical significance of urine heparanase in bladder cancer progression.

Authors:  Itay Shafat; Dov Pode; Tamar Peretz; Neta Ilan; Israel Vlodavsky; Benjamin Nisman
Journal:  Neoplasia       Date:  2008-02       Impact factor: 5.715

10.  Syndecan-1 and FGF-2, but not FGF receptor-1, share a common transport route and co-localize with heparanase in the nuclei of mesenchymal tumor cells.

Authors:  Fang Zong; Eleni Fthenou; Nina Wolmer; Péter Hollósi; Ilona Kovalszky; László Szilák; Carolin Mogler; Gustav Nilsonne; Georgios Tzanakakis; Katalin Dobra
Journal:  PLoS One       Date:  2009-10-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.